The Clinical Use Of Cystatin C In Patients With My Eloma

Background: Cystatin C(Cys C) is thought to be synthesised by all nucleat ed cells and freely filtered by the kidney, which has been proposed as a mark er for glomerular filtration rate(GFR). However, some has reported that it may be over-expressed in some tumour cells and lead to an increased circulating le vel. The aim of the present study is to determine whether Cys C can be used as an accurate GFR marker in patients with multiple myeloma (MM) and eva luate the correlation between Cys C and MM clinical stage and turmor burden. Methods: We investigated the serum Cys C , serum creatinine (Scr) , blood u rea nitrogen (BUN) , β2-microglobulin, the paraprotein concentration,serum calc ium and hemoglobin levels in 31 patients with myeloma and 50 normal control s.We compare serum Cys C with Scr, BUN, β 2-microglobulin, paraprotein,seru m calcium,hemoglobin and the clinical stage according to international staging system (ISS) for multiple myeloma patients. Results: Serum level of Cys C in patients with MM is much higher than normal control .There is 13 MM patie nts(41.94%) beyond the upper limitation but only 38.71 % and 35.48% for Scr and BUN Cys C is well correlated with β2- microglobulin (r=0.786, p<0.00 1) , but not with β 2-micoroglobulin/Scr.There is also no correlation between Cys C and paraprotein ,albumin,hemoglobin or clonal plasma cell percent. Cys C is partially correlated with MM stage (r=0.469, p=0.001) and serum calc ium concentration (r=0. 470, p=0. 011) . Conclusion:Serum Cys C is an acc urate GFR marker and well correlated with disease stage for patients with my eloma...